Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator–controlled phase 3 AMAGINE-2 trial

Name: Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator–controlled phase 3 AMAGINE-2 trial
Creator: Luis Puig
Published: 2019-06-03T15:24:24.075Z
Keywords: Safety, Psoriasis, Efficacy Assessment

Puig, Luis; Lebwohl, Mark; Bachelez, Herve; Sobell, Jeffrey; Jacobson, Abby

doi:10.17632/6jghtvc333.1

Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator–controlled phase 3 AMAGINE-2 trial

Published: 3 June 2019| Version 1 | DOI: 10.17632/6jghtvc333.1

Contributors:

Luis Puig, Mark Lebwohl, Herve Bachelez, Jeffrey Sobell, Abby Jacobson

Description

Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator–controlled phase 3 AMAGINE-2 trial

Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator–controlled phase 3 AMAGINE-2 trial

Description

Files

Categories

Licence